Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 9/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | ME2 | P23368 | 1/20 | 0.37 |
| ▸ | ME1 | P48163 | 1/20 | 0.37 |
| ▸ | ME3 | Q16798 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815233 | 0.90 | PKM (0.39) | LIPECNR1ME2ME1ME3 | |
| SCHEMBL14815376 | 0.88 | LIPE (0.38) | LIPECNR1PIK3CAPRKAA2 | |
| SCHEMBL14815136 | 0.88 | LIPE (0.42) | LIPEPIK3CAPRKAA2 | |
| SCHEMBL14814935 | 0.88 | NTRK1 (0.34) | LIPECNR1 | |
| SCHEMBL14815458 | 0.87 | GAA (0.41) | CNR1PIK3CAPRKAA2 | |
| SCHEMBL14815272 | 0.84 | CCR3 (0.40) | — | |
| SCHEMBL14815210 | 0.84 | LIPE (0.41) | LIPEPIK3CAPRKAA2 | |
| SCHEMBL14814936 | 0.83 | LIPE (0.39) | LIPE | |
| SCHEMBL14815447 | 0.83 | DPP4 (0.36) | LIPE | |
| SCHEMBL14814700 | 0.83 | KDM4E (0.44) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | LIPE 4720/4885CNR1 324/4885HRH3 1244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.